MedTrace Logo

First-Line and Neoadjuvant Immunotherapy for Gastric Cancer

NCT06727981 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-12-11

No results posted yet for this study

Summary

This prospective observational study aims to evaluate the efficacy and safety of immune checkpoint inhibitors as first-line and neoadjuvant therapy for advanced gastric cancer, while also investigating relevant biomarkers to better understand their role in immunotherapy outcomes

Conditions

  • Advanced Gastric Cancer
  • Locally Advanced Gastric Carcinoma

Interventions

DRUG

ICI plus Chemothearpy

This intervention involves the administration of immune checkpoint inhibitors (ICIs) in combination with standard chemotherapy.

DRUG

Chemotherapy

This intervention involves the administration of standard chemotherapy alone.

Sponsors & Collaborators

  • Qilu Hospital of Shandong University

    lead OTHER

Principal Investigators

  • Lian Liu, MD · Qilu Hospital of Shandong University

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-15
Primary Completion
2027-01-15
Completion
2028-01-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06727981 on ClinicalTrials.gov